Neurofibromatosis von Recklinghausen type 1 - Current knowledge;Neurofibromatosis von Recklinghausen typ 1 - Současné znalosti

Ceska a Slovenska Neurologie a Neurochirurgie

Volumn 67, Issue 5, 2004, Pages 315-320

  Petrák, Borivoj ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Clinical findings; Diagnostic criteria; Neurofibromatosis von Recklinghausen type 1; Neurofibromin

Indexed keywords

DNA; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; NEUROFIBROMIN; RAS PROTEIN;

ARTICLE; ATTENTION; AUTOSOMAL DOMINANT INHERITANCE; BEHAVIOR DISORDER; BENIGN TUMOR; BONE DYSPLASIA; BONE LESION; BONE MALFORMATION; BRAIN BLOOD VESSEL; BRAIN RADIOGRAPHY; CAFE AU LAIT SPOT; CANCER INHIBITION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHROMOSOME 17Q; CLINICAL FEATURE; COGNITIVE DEFECT; DEVELOPMENTAL DISORDER; DIAGNOSTIC TEST; DNA DETERMINATION; ENDOCRINE DISEASE; ENZYME INACTIVATION; FIBROBLAST; FIBROMUSCULAR DYSPLASIA; GENE LOCATION; GENE MUTATION; GROWTH REGULATION; HEALTH EDUCATION; HUMAN; HYDROLYSIS; HYPERTENSION; INCIDENCE; INGUINAL REGION; KIDNEY ARTERY; LEARNING DISORDER; LENTIGO; LONG BONE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MAST CELL; MICROCEPHALY; NEUROECTODERM; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE GLIOMA; PHAKOMATOSIS; POPULATION RESEARCH; PRENATAL DIAGNOSIS; PREVALENCE; PROTEIN DEPLETION; PROTEIN FUNCTION; SCHWANN CELL; SCOLIOSIS; SHORT STATURE; SKIN NODULE; SPHENOID; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; TISSUE DIFFERENTIATION; TREATMENT PLANNING;

EID: 7944225426     PISSN: 12107859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Berg BO. Current concepts of neurocutaneous disorders. Brain Dev 1991; 13: 9-20.
2. De Clue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, et al. Abnormal regulation of mammalian p21 RAS contributed to malignant tumor growth in von Recklinghausen (Type 1) neurofibromatosis. Cell 1992; 69: 265-273.
3. Qian F, Germino GG. "Mistakes happen": Somatic mutation and diasease. Am J Hum Genet 1997; 61: 1000-1005.
4. Tischfield JA. Loss of heterozygosity or: How I learned to stop worrying and love mitotic recombination. Am J Hum Genet 1997; 61: 995-999.
5. Berg BO. Neurocutaneous syndromes: Phakomatoses and allied conditions. In: Swaiman KF, editor. Pediatric neurologic diseases. New York: Mosby-Year Book, Inc.; 1994. p. 1045-1069.
6. Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis. 2nd ed. Baltimore: John Hopkins University Press; 1992.
7. Huson SM. The neurofibromatoses: diagnostic, classification and clinical features [abstract]. In: Proceedings of the International Conference on Neurocutaneus Syndromes (Phacomatoses); 1995 May 12-13; Warsaw, Polen. 1995. p. 126-128.
8. Schulz ES, Kaufmann D, Tinschert S, Schell H, Driesch von den P, Schuller G. Segmental neurofibromatosis. Case report. Dermatology 2002; 204: 296-297.
9. Carey JC, Viskochil DH. Neurofibromatosis type 1: A model condition for the study of the molecular basis of variable expressivity in human disorders. Am J Med Genet 1999; 89: 7-13.
10. Tinschert S, Naumann I, Stegmann E, Buske A, Kaufmann D, Thiel G, et al. Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 2000; 8(6): 455-459.
11. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999; 89: 1-6.
12. Cawthon RM, Weiss R, Xu G, Viskochil D, Culver M, Stevens J, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutation. Cell 1990; 62: 193-201.
13. Platten M, Giordano MJ, Dirven CMF, Gutmann DM, Louis DN. Up-regulation of specific NF1 gene transkrips in sporadic pilocytic astrocytomas. Am J Pathol 1996; 149(2): 621-627.
14. Lázaro C, Ravella A, Gaona A, Volpini V, Estvill X. Neurofibromatosis type I due to germ-line mosaicism in a clinically normal father. N Engl J Med 1994; 331: 1403-1407.
15. Ruggieri M, Huson S. The clinical and diagostic implications of mosaicism in the neurofibromatosis. Neurology 2001; 56: 1433-1443.
16. Upadhyaya M, Roberts SH, Maynard J, Souror E, Thompson PW, Vaughan M. A cytogenetic deletion, del (17) (q11.22q21.1), in a patient with sporadic neurofibromatosis type 1 (NF1) associated with dysmorphism and developmental delay. J Med Genet 1996; 33(2): 148-152.
17. Xu G, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990; 62: 599-608.
18. Skuse GR, Cappione AJ. RNA processing and clinical variability in neurofibromatosis type 1 (NF1). J Hum Mol Genet 1997; 6(10): 1707-1712.
19. Lau N, Feldkamp MM, Roncari L, Loehr AH, Shannon P, Gutmann DH, et al. Loss of neurofibromin is associated with activation of ras/MAPK and PI3-K/Akt signaling in neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000; 59(9): 759-767.
20. Packer RJ, Gutmann DH, Rubenstein A, Viskochil D, Zimmerman RA, Vezina G, et al. Plexiform neurofibromas in NF1. Toward biologic-based therapy. Neurology 2002; 58: 1461-1470.
21. Weiss B, Bollag G, Shannon K. Hyperactive ras as therapeutic target in neurofibromatosis type 1. Am J Med Genet 1999; 89: 14-22.
22. Cappione AJ, French BL, Skuse GR. A potential role for NF1 mRNA editing in the pathogenesis of NF1 tumors. Am J Hum Genet 1997; 60: 305-312.
23. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist 2000; 5(6): 477-485.
24. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286: 2172-2176.
25. Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM. Expression of p27-Kip and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27-Kip in malignant transformation of neurofibromas. Am J Pathol 1999; 155(6): 1885-1891.
26. Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C, Woodruff JM. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 1999; 155(6): 1855-1860.
27. Liapis H, Marley EF, Lin Y, Dehner LP. p53 and M-67 proliferating cell nuclear antigen in benign and malignant nerve sheath tumors in children. Pediatr Dev Pathol 1999; 2: 377-384.
28. Nielsen GP, Stemmer-Rachaminov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 1999; 155(6): 1879-1884.
29. Jadayel D, Fain P, Upadhyaya M, Ponder MA, Huson SM, Carey J, et al. Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature 1990; 343: 558-559.
30. Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type I (NFI): Evidence for modifying genes. Am J Hum Genet 1993; 53: 305-313.
31. National Institutes of Health Consensus Development Conference. Neurofibromatosis: Conference statement. Arch Neurol 1988; 45 (May): 575-578.
32. Obringer AC, Meadows AT, Zackai EM. The diagnosis of neurofibromatosis in the child under the age of 6 years. Am J Dis Child 1989; 143: 717-719.
33. Arnsmeier SL, Riccardi VM, Paller AS. Familial multiple cafe au lait spots. Arch Dermatol 1994; 130(11):1425-1426.
34. Curless RC, Siatkowski M, Shatz AJ. MRI diagnosis of NF1 in children without café-au-lait skin lesions. Pediatr Neurol 1998; 18(3): 269-271
35. DeBella K, Poskitt K, Szudek J, Friedman JM. Use of "unidentified bright objects" on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 2000; 54: 1646-1650.
36. Friedman JM, Gutmann DH, MacColin M. Neurofibromatosis: phenotype, natural history and pathogenesis. 3rd ed. Baltimore: Johns Hopkins University Press; 1999.
37. Korf BR. Plexiform neurofibromas. Am J Med Genet 1999; 89: 31-37.
38. Rutkowski J, Wu K, Gutmann DH, Boyer PJ, Legius E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet 2000; 9(7): 1059-1066.
39. Woodruff JM, Lourea HP, Louis DN, Scheitauer BW. Neurofibroma. In: Kleihues P, Cavenee WK, editors. World Health Organization classification of tumors, pathology and genetics of tumors of nervous system. Lyon: IARC Press; 2000. p.167-168.
40. Serra E, Puig S, Otero D, Gaona A, Kruyer H, Ars E, et al. Confirmation of a double hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 1997; 61: 512-519.
41. Poyhonen M, Leisti E-L, Kytola S, Leisti J. Hereditary spinal neurofibromatosis: a rare form of NF1?. J Med Genet 1997; 34: 184-187.
42. Waggoner DJ, Towbin J, Gottesman G, Gutmann DH. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet 2000; 92: 132-135.
43. Petrák B. Neurokutánní syndromy - klinický obraz a jeho variabilita v dětském věku. Nové možnosti diagnostiky, léč by a sledování [kandidátská disertač ní práce]. Praha: UK 1. LF; 2001.
44. King AA, DeBaun MR, Riccardi VM, Gutmann DH. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 2000; 93: 388-392.
45. Woodruff JM. Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am J Med Genet 1999, 89: 23-30.
46. Wanebo JE, Malik JM, VandenBerg SR, Wanebo HJ, Driesen N, Persing JA. Malignant peripheral nerve shath tumors. A clinicopathologic study of 28 cases. Cancer 1993; 71: 1247-1253.
47. Leroy K, Dumas V, Martin-Garcia N, Falzone MC, Visin MC, Wechsler J, et al. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol 2001; 137(7): 908-913.
48. Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF, et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000; 68: 353-357.
49. Korf BR. Ophthalmological issues in the neurofibromatoses. J Ped Ophthalmol Strabismus 1996; 33(4): 255-259.
50. Recupero SM, Plateroti R, Abdolrahimzadeh S, De-Dominicis M, Giustini S, Noviello MR, et al. Lisch nodules in neurofibromatosis type 1: Relationship to age and cutaneous neurofibromas. Ann Ophthalmology-Glaucoma 1996; 28(3): 178-183.
51. Petrák B, Filouš A. Význam vyš etření předního segmentu oka pro diagnostiku neurofibromatosis von Recklinghausen. Čs pediatr 1998; 53(6): 328-331.
52. Commitee of Genetics, Seashore MR, editor. Health supervision for children with neurofibromatosis. Pediatrics 1995; 96(2): 368-372.
53. Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study. J Pediatr 1994; 125: 63-66.
54. Listernick R, Darling C, Greenwald M, Straus L, Charrow J. Optic pathway tumors in children: The effect of neurofibromatosis type 1 on clinical and natural history. J Pediatrics 1995; 127: 718-722.
55. Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 1999; 89: 38-44.
56. Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatr 1995; 126: 364-367.
57. Kuenzle C, Weissert M, Roulet E, Bode H, Schefer S, Huisman Th, et al. Follow-up of optic pathway gliomas in children with neurofibromatosis type 1. Neuropediatrics 1994; 25: 295-300.
58. Deliganis AV, Gever JR, Berger MS. Prognostic significance of type 1 neurofibromatosis (von Recklinghausen disease) in childhood optic glioma. Neurosurgery 1996; 38: 1114-1118.
59. Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997; 41(2): 143-149.
60. Shuper A, Horev G, Kornreich L, Michowitz S, Weitz R, Zaizov R, et al. Visual pathway glioma: an erratic tumour with therapeutic dilemmas. Arch Dis Child 1997; 76: 259-263.
61. Pletcher BA. Neurofibromatosis Type 1. eMedicine Journal 2002; 3(1).
62. Sevick RJ, Barkowich AJ, Edwards MSB, Koch T, Berg B, Lembert T. Evolution of white matter lesions in neurofibromatosis type 1: MR findings. AJR 1992; 159: 171-175.
63. DiMario FJ, Ramsby G. Magnetic resonanace imaging lesion analysis in neurofibromatosis type 1. Arch Neurol 1998; 55: 500-505.
64. Katzman GL, Dagher AP, Patronas NJ. Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic, volunteers. JAMA, 1999; 282(1): 36-39.
65. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278: 51-57.
66. Rosenbaum T, Engelbrecht V, Krölls W, Dorsten van FA, Hoehn-Berlage M, Lenard HG. MRI abnormalities in neurofibromatosis type 1 (NF1):a study of men and mice. Brain Dev 1999, 21: 268-273.
67. Wolkenstein P, Fréche B, Zeller J, Revuz J. Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. Arch Dermatol 1996; 132: 1333-1336.
68. Kato M, Mizuguchi M, Mattori S, Nakamura S, Takashima S. Loss of neurofibromin in the leptomeningeal astroglial heterotopia of NF-1. Pediatr Neurol 1998; 18(3): 227-230.
69. Castillo M, Green C, Kwock L, Smith K, Wilson D, Schiro S, et al. Proton MR spectroscopy in patients with neurofibromatosis type 1: Evaluation of hamartomas and clinical correlation. AJNR 1995; 16: 141-147.
70. DiPaolo DP, Zimmerman RA, Borke LB, Zackai EH, Bilaniuk LT, Yachnis AT. Neurofibromatosis type 1: Pathologic substrate of high-signal-intensity foci in the brain. Radiology 1995; 195: 721-724.
71. Balestri P, Lucignani G, Fois A, Magliani L, Calistri L, Grana C, et al. Cerebral glucose metabolism in neurofibromatosis type 1 assesed with /18F/-2-fluoro-2-deoxy-D-glucose and PET. J Neurol Neurosurg and Psychiatry 1994; 57: 1479-1483.
72. Hofman KJ, Harris EL, Bryan RN, Dencla MB. Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 1994; 124: S1-8.
73. Ozonoff S. Cognitive impairment in neurofibromatosis type 1. Am J Med Genet 1999; 89: 45-52.
74. Ferner RE, Chaudhuri R, Bingham J, Cox T, Hughes RAC. MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationships to intellectual impairment. J Neurol Neurosurg Psychiatry 1993; 56: 492-495.
75. North K, Joy P, Yuille D, Cocks N, Mobbs E, Hutchins P, et al. Specific learning disability in children with neurofibromatosis type 1: Significance of MRI abnormalities. Neurology 1994; 44: 878-883.
76. Horikawa M, Utunomiya H, Hirotaka S, Yamada S, Ohtaki E, Matsvishi T. Case of von Recklinghausen disease associated with cerebral infarction. J Child Neurol 1997; 12(2): 144-146.
77. Kestle JR, Hoffman HJ, Mock AR. Moyamoya phenomenon after radiation for optic glioma. J Neurosurg 1993; 79: 32-35.
78. Fossali E, Signorini E, Intermite RC, Casalini E, Lovaria A, Maninetti MM, et al. Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol 2000; 14: 806-810.
79. Molloy PT, Bilaniuk LT, Vaughan SN, Needle MN, Liu GT, Zackai EM, et al. Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurology 1995; 45: 1897-1902.
80. Pollack IF, Shultz B, Mulvihill JJ. The management of brainstem gliomas in patients with neurofibromatosis. Neurology 1996; 46: 1652-1660.
81. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1.728 patients. Am J Med Genet 1997; 70: 138-143.
82. Korf BR, Carrazana E, Holmes GL. Patterns of seizures observed in association with neurofibromatosis 1. Epilepsia 1993; 34(4): 616-620.
83. Lund AM, Skovby F. Optic gliomas in children with neurofibromatosis type1. Eur J Pediatr 1991; 150: 835-838.
84. Jabbari B, Maitland ChG, Morris LM, Morales J, Gunderson CH. The value of visual evoked potential as a screening test in neurofibromatosis. Arch neurol 1985; 42: 1072-1074.
85. Jenkin D, Angyalfi S, Becker L, Berry M, Buncic R, Chan H, et al. Optic glioma in children: surveillance, resection, or irradiation. Int J Oncol Biol Phys 1993; 25: 215-225.
86. Listernick R, Charrow J, Tomita T, Goldman S. Carboplatin therapy for optic pathway tumors in children with neurofibromatosis type 1. J Neurooncol 1999; 45: 185-190.
87. Needle MN, Cnaan A, Dattilo J, Chatten J, Phillips PC, Shochat S, et al. Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience 1974-1994. J Pediatr 1997; 131: 678-682.
88. Riccardi VM. A controled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol 1993; 129: 577-581.
89. Upadhyaya M, Cooper DN. The mutation spectrum in neurofibromatosis type1 and its underlying mechanism. In: Upadhyaya M, Cooper DN, editors. Neurofibromatosis type 1: from genotype to phenotype. Oxford: BIOS Scientific Publisher; 1998. p. 65-68.